VRTX

Vertex Pharmaceuticals
D

VRTX

429.48
USD
1.47
(0.34%)
مفتوح الان
حجم التداول
20,950
الربح لكل سهم
18
العائد الربحي
-
P/E
-226
حجم السوق
110,668,061,792
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
الأفكار والتحليلات
    هشام منسي
    هشام منسي
    منذ 5 أشهر
    buy
    VRTX
    VRTX
    2024-08-22 10:31
    VRTX Chart
    المزيد
أصول ذات صلة
    AMGN
    AMGN
    -0.46
    (-0.17%)
    274.41 USD
    BIIB
    BIIB
    2.170
    (1.54%)
    143.110 USD
    B
    BMRN
    -0.500
    (-0.80%)
    61.990 USD
    E
    EXEL
    -3.660
    (-10.04%)
    32.780 USD
    GILD
    GILD
    0.240
    (0.26%)
    93.190 USD
    I
    INCY
    -0.540
    (-0.74%)
    72.930 USD
    I
    IONS
    0.210
    (0.64%)
    32.890 USD
    REGN
    REGN
    -2.95
    (-0.43%)
    684.37 USD
    المزيد
الأخبار
المقالات

العنوان: Vertex Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.